Companie

Russian vaccine 'Sputnik V' gets emergency use nod from regulatory panel

Our Bureau. New Delhi | Updated on April 12, 2021

Sputnik V at Panacea Biotec sites will be supplied to the international partners of RDIF.   -  REUTERS

Developed by Gamaleya Research Institute of Epidemiology and Microbiology, this adenovirus vector vaccine is claimed to have over 91 per cent efficacy.

As the number of daily Covid-19 cases going up in India surpassing those reported during the first wave of the pandemic last year, the independent panel of drug regulatory experts in the country on Monday gave emergency use approval to the Russian Covid-19 vaccine, Sputnik V.

Sputnik V, whose trials were undertaken by the Hyderabad-based Dr Reddy’s Laboratories, became the third Covid-19 vaccine to receive emergency use authorisation after Covishield and Covaxin.

Developed by Gamaleya Research Institute of Epidemiology and Microbiology, this adenovirus vector vaccine is claimed to have over 91 per cent efficacy and is already registered in 59 countries. Several pharma companies have signed contracts with Russian Direct Investment Fund to manufacture several hundred million doses of Sputnik V vaccine in India.

 

Published on April 12, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Covid-19
vaccines and immunisation
Dr Reddys Laboratories Ltd
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.